keyword
MENU ▼
Read by QxMD icon Read
search

Azilsartan

keyword
https://www.readbyqxmd.com/read/27829955/efficacy-and-safety-of-a-single-pill-fixed-dose-combination-of-azilsartan-and-amlodipine
#1
Kota Motozato, Shin-Ichiro Miura, Yuhei Shiga, Takaaki Kusumoto, Keijiro Saku
BACKGROUND: Guidelines for the management of hypertension recommend the use of drugs with different mechanisms of action in antihypertensive regimens that include single-pill fixed-dose combinations of medications. There is some controversy regarding which single-pill fixed-dose combinations of angiotensin II type 1 receptor blockers (ARBs) and calcium channel blockers (CCBs) are effective at reducing blood pressure (BP). METHODS: Forty hypertensive patients who were receiving a single-pill fixed-dose combination of valsartan 80 mg/day and amlodipine 5 mg/day or irbesartan 100 mg/day and amlodipine 5 mg/day were enrolled...
December 2016: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/27824680/angiotensin-ii-receptor-blockers-following-intravenous-nicardipine-administration-to-lower-blood-pressure-in-patients-with-hypertensive-intracerebral-hemorrhage-a-prospective-randomized-study
#2
Joji Inamasu, Shunsuke Nakae, Kazuhide Adachi, Yuichi Hirose
BACKGROUND AND OBJECTIVE: In patients with hypertensive intracerebral hemorrhage (HICH), intravenous nicardipine is primarily used to lower blood pressure (BP). However, there are few studies investigating the role of oral antihypertensives administered after intravenous nicardipine to prevent BP from rising. Angiotensin II receptor blockers (ARBs) may be beneficial in HICH patients not only as antihypertensives but also by lowering plasma catecholamine levels. A prospective randomized study was conducted between January 2015 and March 2016 to comparatively evaluate the efficacy of two ARBs (azilsartan vs...
November 7, 2016: Blood Pressure Monitoring
https://www.readbyqxmd.com/read/27731574/azilsartan-novel-angiotensin-receptor-blocker
#3
Ramesh R Dargad, Jai D Parekh, Rohit R Dargad, Shweta Kukrety
OBJECTIVE: To describe the efficacy and safety profile of the new angiotensin receptor blocker (ARB), "Azilsartan Medoxomil", reviewing data available from both clinical and pre-clinical studies. MATERIAL: We completed a review of the English literature from PubMed using the keywords- azilsartan medoxomil, angiotensin receptor blockers (ARB), angiotensin converting enzyme inhibitors (ACEi) and hypertension. DATA EVALUATION: Many clinical trials have been conducted comparing the efficacy of azilsartan with other ARB's and also with the ACEi ramipril...
March 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27635180/depressor-and-anti-inflammatory-effects-of-angiotensin-ii-receptor-blockers-in-metabolic-and-or-hypertensive-patients-with-coronary-artery-disease-a-randomized-prospective-study-diamond-study
#4
Sen Adachi, Shin-Ichiro Miura, Yuhei Shiga, Tadaaki Arimura, Takashi Kuwano, Ken Kitajima, Amane Ike, Makoto Sugihara, Atsushi Iwata, Hiroaki Nishikawa, Natsumi Morito, Keijiro Saku
BACKGROUND: We compared the efficacy and safety of azilsartan to those of olmesartan in a prospective, randomized clinical trial. METHODS: Forty-four hypertensive patients who had coronary artery disease (CAD) were enrolled. We randomly assigned patients to changeover from their prior angiotensin II receptor blockers (ARBs) to either azilsartan or olmesartan, and followed the patients for 12 weeks. RESULTS: Office systolic blood pressure (SBP) in the azilsartan group was significantly decreased after 12 weeks...
October 2016: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/27558280/the-impact-of-azilsartan-medoxomil-treatment-capsule-formulation-at-doses-ranging-from-10-to-80%C3%A2-mg-significant-rapid-reductions-in-clinic-diastolic-and-systolic-blood-pressure
#5
Alfonso Perez, Charlie Cao
In this phase 2, multicenter, parallel-group, double-blind, dose-ranging study, hypertensive adults (n=449) were randomized to receive one of five doses of a capsule formulation of azilsartan medoxomil (AZL-M; 5, 10, 20, 40, 80 mg), olmesartan medoxomil (OLM) 20 mg, or placebo once daily. The primary endpoint was change in trough clinic diastolic blood pressure (DBP) at week 8. AZL-M provided rapid statistically and clinically significant reductions in DBP and systolic blood pressure (SBP) vs placebo at all doses except 5 mg...
August 25, 2016: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/27536242/azilsartan-as-a-potent-antihypertensive-drug-with-possible-pleiotropic-cardiometabolic-effects-a-review-study
#6
REVIEW
Georgios Georgiopoulos, Vasiliki Katsi, Dimitrios Oikonomou, Georgia Vamvakou, Evangelia Koutli, Aggeliki Laina, Constantinos Tsioufis, Petros Nihoyannopoulos, Dimitrios Tousoulis
BACKGROUND: Hypertension related cardiovascular (CV) complications could be amplified by the presence of metabolic co-morbidities. Azilsartan medoxomil (AZL-M) is the eighth approved member of angiotensin II receptor blockers (ARBs), a drug class of high priority in the management of hypertensive subjects with diabetes mellitus type II (DMII). METHODS: Under this prism, we performed a systematic review of the literature for all relevant articles in order to evaluate the efficacy, safety, and possible clinical role of AZL-M in hypertensive diabetic patients...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27535187/a-case-of-lithium-intoxication-induced-by-an-antihypertensive-angiotensin-1-subtype-specific-angiotensin-ii-receptor-blocker-in-an-elderly-patient-with-bipolar-disorder-and-hypertension
#7
Yuichi Hayashi, Shohei Nishida, Akira Takekoshi, Muneharu Murakami, Megumi Yamada, Akio Kimura, Akio Suzuki, Takashi Inuzuka
Lithium carbonate is considered to be a first-line treatment for bipolar disorder; however, this drug has a narrow therapeutic window, and lithium intoxication is commonly induced by various drugs interaction and situations. We herein report a case of lithium intoxication induced by the administration of an antihypertensive agent targeting the angiotensin 1 (AT1) subtype of the angiotensin II receptor in a 65-year-old woman with a 40-year history of bipolar disorder type 1, and 1-year history of essential hypertension...
2016: Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics
https://www.readbyqxmd.com/read/27514506/effects-of-food-intake-on-the-pharmacokinetics-of-azilsartan-medoxomil-and-chlorthalidone-alone-and-in-fixed-dose-combination-in-healthy-adults
#8
Caroline Dudkowski, Aziz Karim, Melvin Munsaka
Azilsartan medoxomil is a long-acting angiotensin II receptor blocker used to treat hypertension as monotherapy or in fixed-dose combination (FDC) with chlorthalidone. This study assessed the effects of food intake on the plasma pharmacokinetics of the active moiety, azilsartan, and of chlorthalidone when administered as separate tablets or in FDC. Cohort 1 (n = 24) received azilsartan medoxomil (80 mg) and chlorthalidone (25 mg) once in a fasted condition and once 30 minutes after the initiation of a high-fat meal (fed)...
September 2016: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/27424785/antihypertensive-efficacy-and-safety-of-the-angiotensin-receptor-blocker-azilsartan-in-elderly-patients-with-hypertension
#9
Tomohito Kamada, Mutsuharu Hayashi, Wakaya Fujiwara, Daiji Yoshikawa, Daisuke Mukaide, Yoshinori Sugishita, Masataka Yoshinaga, Takehiro Itoh, Hiroatsu Yokoi, Junichi Ishii, Eiichi Watanabe, Yukio Ozaki, Hideo Izawa
OBJECTIVES: The number of elderly patients with hypertension has been steadily increasing. However, there are limited data on the safety and efficacy of the new angiotensin type 1 receptor blocker (ARB) azilsartan in elderly patients with hypertension. We investigated the clinical efficacy and safety of azilsartan in this population. METHODS: The study population comprised 56 ambulatory patients with essential hypertension. We evaluated the reduction in blood pressure and safety after 12 weeks of treatment with azilsartan in 29 hypertensive patients ≥65 years of age (aged group) in comparison with the findings in 27 patients <65 years of age (non-aged group)...
July 17, 2016: Drug and Chemical Toxicology
https://www.readbyqxmd.com/read/27421242/azilsartan-in-patients-with-mild-to-moderate-hypertension-using-clinic-and-ambulatory-blood-pressure-measurements
#10
Alfonso Perez, Charlie Cao
This was a phase 2, multicenter, randomized, parallel-group, double-blind dose-ranging study. Hypertensive adults (n=555) received one of five doses of azilsartan (AZL; 2.5, 5, 10, 20, 40 mg), olmesartan medoxomil (OLM) 20 mg, or placebo once daily. The primary endpoint was change in trough clinic diastolic blood pressure (DBP) at week 8. Compared with placebo, all AZL doses (except 2.5 mg) provided statistically and clinically significant reductions in DBP and systolic blood pressure (SBP) based on both clinic blood pressure (BP) and 24-hour ambulatory BP monitoring (ABPM)...
July 15, 2016: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/27321284/at1-receptor-blocker-azilsartan-medoxomil-normalizes-plasma-mir-146a-and-mir-342-3p-in-a-murine-heart-failure-model
#11
Manami Kaneko, Tomoko Satomi, Shuji Fujiwara, Hidefumi Uchiyama, Keiji Kusumoto, Tomoyuki Nishimoto
Our study measured circulating microRNA (miRNA) levels in the plasma of calsequestrin (CSQ)-tg mouse, a severe heart failure model, and evaluated whether treatment with angiotensin II type 1 receptor blocker, azilsartan medoxomil (AZL-M) influenced their levels using miRNA array analysis. MiR-146a, miR-149, miR-150, and miR-342-3p were reproducibly reduced in the plasma of CSQ-tg mice. Among them, miR-146a and miR-342-3p were significantly restored by AZL-M, which were associated with improvement of survival rate and reduction of congestion...
June 20, 2016: Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
https://www.readbyqxmd.com/read/27259699/relationship-between-obesity-hypertension-and-aldosterone-production-in-postmenopausal-african-american-women-a-pilot-study
#12
Luke J Laffin, Colleen Majewski, Chuanhong Liao, George L Bakris
Increased abdominal obesity is associated with increased cardiovascular risk, especially in African American women. The adipocyte is documented to produce a number of inflammatory factors including the hormone aldosterone. There are very few data documenting aldosterone production from adipocytes of postmenopausal women as well as data demonstrating the effects of angiotensin receptor blockade (ARB) on its production in predominately African American women. The authors hypothesize that increased central adipocyte mass in obese postmenopausal women contributes to increased production of aldosterone that is suppressed with the ARB azilsartan medoxomil...
June 4, 2016: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/27216792/drug-interactions-with-angiotensin-receptor-blockers-role-of-human-cytochromes-p450
#13
REVIEW
Ruirui Yang, Zhiqiang Luo, Yang Liu, Mohan Sun, Ling Zheng, Yingying Chen, Yanping Li, Hao Wang, Lingzhu Chen, Ming Wu, Huihui Zhao
BACKGROUND: Angiotensin receptor blockers (ARBs) are the most recent class of agents for the treatment of hypertension. However, ARBs may cause a low incidence of headache, upper respiratory infection, back pain, muscle cramps, fatigue, dizziness, and many other side effects. In some cases, such toxicity is associated with pharmacokinetic alterations. METHODS: The cytochrome P450 (CYP) enzyme system plays an important role in a lot of clinically important pharmacokinetic drug interactions...
2016: Current Drug Metabolism
https://www.readbyqxmd.com/read/27130806/angiotensin-ii-type-1-receptor-antagonists-in-animal-models-of-vascular-cardiac-metabolic-and-renal-disease
#14
REVIEW
Martin C Michel, Hans R Brunner, Carolyn Foster, Yong Huo
We have reviewed the effects of angiotensin II type 1 receptor antagonists (ARBs) in various animal models of hypertension, atherosclerosis, cardiac function, hypertrophy and fibrosis, glucose and lipid metabolism, and renal function and morphology. Those of azilsartan and telmisartan have been included comprehensively whereas those of other ARBs have been included systematically but without intention of completeness. ARBs as a class lower blood pressure in established hypertension and prevent hypertension development in all applicable animal models except those with a markedly suppressed renin-angiotensin system; blood pressure lowering even persists for a considerable time after discontinuation of treatment...
August 2016: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27116201/study-on-enhanced-dissolution-of-azilsartan-loaded-solid-dispersion-prepared-by-combining-wet-milling-and-spray-drying-technologies
#15
Tianshu Lu, Yinghua Sun, Dawei Ding, Qi Zhang, Rui Fan, Zhonggui He, Jing Wang
The purpose of this study was to develop a combination method of wet milling and spray-drying technologies to prepare the solid dispersion and improve the dissolution rate of poorly water-soluble drug candidates. Azilsartan (AZL) was selected as the model drug for its poor water solubility. In the study, AZL-loaded solid dispersion was prepared with polyethylene glycol 6000 (PEG6000) and hydroxypropyl cellulose with super low viscosity (HPC-SL) as stabilizers by using combination of wet grinding and spray-drying methods...
April 26, 2016: AAPS PharmSciTech
https://www.readbyqxmd.com/read/27103882/azilsartan-medoxomil-in-the-management-of-hypertension-an-evidence-based-review-of-its-place-in-therapy
#16
REVIEW
Emiliano Angeloni
BACKGROUND: Azilsartan (AZI) is a relatively new angiotensin receptor blocker available for the treatment of any stage of hypertension, which was eventually given in combination with chlorthalidone (CLT). OBJECTIVE: To review pharmacology and clinical role of AZI monotherapy and AZI/CLT or AZI/amlodipine combination therapies for hypertension management. METHODS: PubMed, Embase, and Cochrane Library were searched using search terms " azilsartan", "chlorthalidone," "pharmacology," "pharmacokinetics," "pharmacodynamics," "pharmacoeconomics," and "cost-effectiveness...
2016: Core Evidence
https://www.readbyqxmd.com/read/27086671/changeover-trial-of-azilsartan-and-olmesartan-comparing-effects-on-the-renin-angiotensin-aldosterone-system-in-patients-with-essential-hypertension-after-cardiac-surgery-chaos-study
#17
Akira Sezai, Shunji Osaka, Hiroko Yaoita, Munehito Arimoto, Hiroaki Hata, Motomi Shiono, Hisakuni Sakino
BACKGROUND: Angiotensin II receptor blockers (ARBs) have been widely used to treat hypertension and large-scale clinical studies have shown various benefits. In this study, we compared olmesartan with azilsartan, the newest ARB. METHODS: The subjects were outpatients who were clinically stable after cardiac surgery. Sixty patients were randomized to receive either azilsartan or olmesartan for 1 year and were switched to the other drug for the following 1 year. The primary endpoints were the levels of plasma renin activity, angiotensin II, and aldosterone...
June 20, 2016: Annals of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/27027425/the-velocity-of-antihypertensive-effects-of-seven-angiotensin-ii-receptor-blockers-determined-by-home-blood-pressure-measurements
#18
Michihiro Satoh, Toshikazu Haga, Miki Hosaka, Taku Obara, Hirohito Metoki, Takahisa Murakami, Masahiro Kikuya, Ryusuke Inoue, Kei Asayama, Nariyasu Mano, Takayoshi Ohkubo, Yutaka Imai
BACKGROUND: We aimed to examine the blood pressure (BP)-lowering effect and the time to attain the maximal antihypertensive effect (stabilization time) of several angiotensin II receptor blockers (ARBs) based on home BP measurements. METHODS: We surveyed consecutive newly diagnosed, untreated patients with hypertension who started the treatment with a mid-level dose of one of seven ARBs (losartan 50 mg, telmisartan 40 mg, candesartan 8 mg, olmesartan 20 mg, valsartan 80 mg, irbesartan 100 mg, or azilsartan 20 mg)...
June 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/26956148/azilsartan-compared-to-ace-inhibitors-in-anti-hypertensive-therapy-one-year-outcomes-of-the-observational-early-registry
#19
Anselm K Gitt, Peter Bramlage, Sebastian A Potthoff, Peter Baumgart, Felix Mahfoud, Hartmut Buhck, Martina Ehmen, Taoufik Ouarrak, Jochen Senges, Roland E Schmieder
BACKGROUND: Azilsartan medoxomil (AZL-M), has been demonstrated to be more effective than the other sartans currently in use; however, there is insufficient information available comparing it with ACE-inhibitors. Therefore, we aimed to compare the efficacy, safety, and tolerability of AZL-M with that of ACE-inhibitors in a real life clinical setting. METHODS: The EARLY registry is a prospective, observational, national, multicentre registry with a follow-up period of 12 months...
2016: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/26879328/azilsartan-an-angiotensin-ii-type-1-receptor-blocker-attenuates-tert-butyl-hydroperoxide-induced-endothelial-cell-injury-through-inhibition-of-mitochondrial-dysfunction-and-anti-inflammatory-activity
#20
Hao Liu, Ping Mao, Jia Wang, Tuo Wang, Chang-Hou Xie
Angiotensin II type 1 receptor (AT1-R) blockers protect against brain ischemia by mechanisms dependent on and independent of arterial blood pressure. However, the effects of AT1-R blockers on brain endothelial cell injury and detailed mechanisms remain unclear. The goal of this study is to investigate whether azilsartan, an AT1-R blocker, could attenuate oxidative injury in endothelial cells via regulating mitochondrial function and inflammatory responses. We found that treatment with azilsartan suppressed tert-butyl hydroperoxide (t-BHP)-induced oxidative damage in murine brain endothelial cells (mBECs) by increasing cell viability, decreasing lactate dehydrogenase (LDH) release and inhibiting cell apoptosis...
March 2016: Neurochemistry International
keyword
keyword
13167
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"